Mölndal, 13 November 2025 - Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B), today publishes, in connection with the ongoing rights issue, preliminary and unaudited financial key figures for the second quarter (August-October 2025) ahead of the interim report scheduled for publication on 21 November 2025.
Preliminary financial results, Q2 2025/26 (Aug-Oct 2025)
Preliminary financial results, May-Oct 2025
The U.S. market continued to develop during the quarter, with sales of SEK 17.9 million (16.6), corresponding to a growth of 7.8 percent (currency-adjusted 18.4%). Sales in EMEA/APAC amounted to SEK 4.5 million (5.2). Cash flow was negatively affected by costs related to the terminated acquisition process with OsteoCentric Technologies.
The company continues to implement the strategic shift announced in February, with a focus on increased commercialization, cost efficiency, and expanded collaborations with leading orthopedic centers in the United States.
"Through the ongoing rights issue, we are strengthening Integrum's financial position and creating room for continued growth," says Martin Hillsten, CEO of Integrum.
The full interim report for the period May-October 2025/26 will be published on 21 November 2025.
This disclosure contains information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 13-11-2025 17:56 CET.